2005 Stoklara Genel Bakış Bir yatırım holding şirketi olan SSY Group Limited, Çin Halk Cumhuriyeti'nde ve uluslararası alanda çeşitli farmasötik ürünleri araştırmakta, geliştirmekte, üretmekte, ticaretini yapmakta ve hastanelere ve distribütörlere satmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
SSY Group Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti SSY Group Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$3.37 52 Haftanın En Yüksek Seviyesi HK$5.20 52 Haftanın En Düşük Seviyesi HK$3.26 Beta 0.62 1 Aylık Değişim -5.87% 3 Aylık Değişim -23.41% 1 Yıllık Değişim -31.92% 3 Yıllık Değişim -14.90% 5 Yıllık Değişim -47.59% Halka arzdan bu yana değişim 29.12%
Son Haberler & Güncellemeler
SSY Group Limited Announces Update on Product Development Dec 30 SSY Group Limited Announces Update on Product Development
SSY Group Limited Announces Update on Product Development Dec 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China Dec 02
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation Nov 27
SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg) Nov 05 Daha fazla güncelleme görün
SSY Group Limited Announces Update on Product Development Dec 30 SSY Group Limited Announces Update on Product Development
SSY Group Limited Announces Update on Product Development Dec 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China Dec 02
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation Nov 27
SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg) Nov 05
SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China Oct 21
SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China Oct 14
Investor sentiment improves as stock rises 18% Oct 02
Chairman & CEO recently bought HK$4.8m worth of stock Sep 25
SSY Group Limited Announces Update on Product Development Sep 09
Chairman & CEO recently bought HK$1.5m worth of stock Sep 04
SSY Group Limited Announces Update on Product Development Sep 02
First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023) Aug 31
First half dividend increased to HK$0.08 Aug 30 SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024
SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 16
SSY Group Limited Announces Update on Product Development Aug 07
Investor sentiment deteriorates as stock falls 16% Jul 29
SSY Group Limited Announces Update on Product Development Jul 23
SSY Group Limited Announces Update on Product Development Jul 16
SSY Group Limited Announces Update on Product Development Jun 29
SSY Group Limited Announces Update on Product Development Jun 24
SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China Jun 18
SSY Group Limited Announces Update on Product Development Jun 08 SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China
SSY Group Limited Announces Update on Product Development May 29
Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China May 28
Upcoming dividend of HK$0.10 per share May 14
SSY Group Limited Provides Update on Product Development Apr 03
Chairman & CEO recently bought HK$2.5m worth of stock Mar 29
SSY Group Limited, Annual General Meeting, May 17, 2024 Mar 28
Full year 2023 earnings released: EPS: HK$0.44 (vs HK$0.38 in FY 2022) Mar 28
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024 Mar 27
SSY Group Limited Announces Update on Product Development Mar 21
SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China Mar 02
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market Mar 01
SSY Group Limited Receives Approval for Gliclazide Tablet Feb 28
SSY Group Limited Provides Update on Product Development Feb 24
SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China Feb 19
SSY Group Limited Announces Update on Product Development Jan 31
SSY Group Limited Provides Update on Product Development Jan 24 SSY Group Limited Appoints Liu Wenjun as Non-Executive Director
Ssy Group Limited Provides Update on Product Development Jan 17
SSY Group Limited Announces Update on Product Development Jan 10
SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China Jan 05
SSY Group Limited Provides Update on Product Development Dec 27
Chairman & CEO recently bought HK$4.7m worth of stock Dec 06
SSY Group Limited Announces Update on Product Development Dec 01
SSY Group Limited Announces Update on Product Development Nov 23
SSY Group Limited Announces Update on Product Development Nov 10
National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045 Nov 09
SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023 Nov 02
SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection Nov 01
SSY Group Limited Announces Update on Product Development Oct 31
SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China Oct 27
SSY Group Limited Provides Update on Product Development Oct 26
SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection Oct 21
SSY Group Limited Obtains the Approval for Drug Production and Registration for Linezolid and Sodium Chloride Injection (300ml) from the National Medical Products Administration of China Oct 18
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Tinidazole Tablets (0.5G) and Ornidazole Tablets (0.5G) from the National Medical Products Administration of China Oct 12
SSY Group Limited Announces Update on Product Development Oct 10
SSY Group Limited Announces Update on Product Development Sep 16
Upcoming dividend of HK$0.07 per share at 3.5% yield Sep 07
SSY Group Limited Announces Update on Product Development Sep 05
SSY Group Limited Provides Update on Product Development Sep 02
First half 2023 earnings released: EPS: HK$0.21 (vs HK$0.19 in 1H 2022) Aug 30
Ssy Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 27 September 2023 Aug 30
SSY Group Limited Announces Update on Product Development Aug 24
SSY Group Limited to Report First Half, 2023 Results on Aug 29, 2023 Aug 18
SSY Group Limited Obtains Approval for Drug Production and Registration for Stiripentol for Suspension (500Mg and 250Mg) from the National Medical Products Administration of China Jul 28
SSY Group Limited Obtains Approval for Drug Production and Registration for Oseltamivir Phosphate for Suspension Jul 14
Chairman & CEO recently bought HK$8.3m worth of stock Jul 08
SSY Group Limited Provides Update on Product Development Jul 07
SSY Group Limited Announces Update on Product Development Jun 30
SSY Group Limited Obtains Approval for Drug Production and Registration for Citicoline Sodium Injection from the National Medical Products Administration of China Jun 14
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Urapidil Hydrochloride Injection Jun 03
SSY Group Limited Announces Update on Product Development May 31
SSY Group Limited Announces the Retirement of Mr. Leung Chong Shun as Independent Non-Executive Director, Chairman of the Remuneration Committee of the Company, A Member F the Audit Committee of the Company and A Member of the Nomination Committee May 20
Upcoming dividend of HK$0.08 per share at 2.8% yield May 16
SSY Group Limited Announces Update on Product Development May 13
SSY Group Limited Announces Update on Product Development May 12
Chairman & CEO recently bought HK$4.9m worth of stock May 10
SSY Group Limited Announces Update on Product Development May 09
Chairman & CEO recently bought HK$2.1m worth of stock Mar 30
Full year 2022 earnings released: EPS: HK$0.38 (vs HK$0.26 in FY 2021) Mar 29
Now 21% undervalued Mar 14
SSY Group Limited Announces the Group's Tinidazole Obtains the Approval for Registration from the National Medical Products Administration of China Feb 07
SSY Group Limited Updates on Product Development Jan 31
SSY Group Limited Obtains the Approval for Registration from the National Medical Products Administration of China to Become A Bulk Drug for the Preparations on the Market Jan 20
SSY Group Limited Obtains Approvals for Drug Production and Registration for Felodipine Sustained-Release Tablets (5mg) and Lacosamide Injection (20ml:0.2g) from the National Medical Products Administration of China Jan 06
Investor sentiment improved over the past week Jan 04
SSY Group Limited Announces Appointment of Jiang Guangce as an Independent Non-Executive Director and Member of Audit Committee, Nomination Committee and Remuneration Committee, with Effect from 1 January 2023 Dec 29
Less than half of directors are independent Nov 16
SSY Group Limited Obtains the Approval for Drug Production and Registration for Azithromycin Tablets (0.25G) from the National Medical Products Administration of China, Being Under Type 4 Chemical Drug and Regarded as Passing the Consistency Evaluation Nov 15
SSY Group Limited Obtains the Approval for Drug Productions from the National Medical Products Administration of China Oct 11 Hissedar Getirileri 2005 HK Pharmaceuticals HK Pazar 7D -5.9% -0.9% 0.3% 1Y -31.9% -7.7% 19.4%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 2005 geçen yıl % -7.7 oranında getiri sağlayan Hong Kong Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: 2005 geçen yıl % 19.4 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 2005's price volatile compared to industry and market? 2005 volatility 2005 Average Weekly Movement 5.1% Pharmaceuticals Industry Average Movement 6.2% Market Average Movement 8.4% 10% most volatile stocks in HK Market 17.7% 10% least volatile stocks in HK Market 3.8%
İstikrarlı Hisse Senedi Fiyatı: 2005 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 2005 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Bir yatırım holding şirketi olan SSY Group Limited, Çin Halk Cumhuriyeti'nde ve uluslararası alanda çeşitli farmasötik ürünleri araştırmakta, geliştirmekte, üretmekte, ticaretini yapmakta ve hastanelere ve distribütörlere satmaktadır. Şirket, PVC olmayan yumuşak torbalar, dik yumuşak torbalar, PP plastik şişeler ve cam şişe infüzyon solüsyonlarının yanı sıra ampul enjeksiyonları da dahil olmak üzere intravenöz infüzyon solüsyonları sunmaktadır. Ayrıca küçük hacimli enjeksiyonlar, oral preparatlar, Çin tıbbı preparatları ve biyolojik preparatların yanı sıra dökme farmasötik ürünler ve tıbbi malzemeler de sağlamaktadır.
Daha fazla göster SSY Group Limited Temel Bilgiler Özeti SSY Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 2005 temel i̇stati̇sti̇kler Piyasa değeri HK$9.97b Kazançlar(TTM ) HK$1.37b Gelir(TTM ) HK$6.47b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 2005 gelir tablosu (TTM ) Gelir HK$6.47b Gelir Maliyeti HK$2.95b Brüt Kâr HK$3.52b Diğer Giderler HK$2.15b Kazançlar HK$1.37b
Temettüler
5.3% Mevcut Temettü Verimi
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/01/02 03:19 Gün Sonu Hisse Fiyatı 2025/01/02 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları SSY Group Limited 22 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Derrick Sun BNP Paribas Securities (Asia) Milo Liu BOCOM International Securities Limited Ying Shao BofA Global Research
Göster 19 daha fazla analist 
